{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:24:39Z","timestamp":1794003879617,"version":"4.8.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejca.2026.117039","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:11:23Z","timestamp":1789085483000},"page":"117039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study"],"prefix":"10.1016","volume":"248","author":[{"given":"Jason","family":"Valent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1741-2795","authenticated-orcid":false,"given":"Jeffrey","family":"Zonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Scott","family":"Swenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Catini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Manwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavna","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilehuma","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2026.117039_bib1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","article-title":"AL Amyloidosis for cardiologists: awareness, diagnosis, and future prospects JACC: CardioOncology state-of-the-art-review","volume":"4","author":"Wechalekar","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.117039_bib2","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3324\/haematol.2019.218859","article-title":"Predicting survival in light chain amyloidosis","volume":"104","author":"Palladini","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.ejca.2026.117039_bib3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.ejca.2026.117039_bib4","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/febs.16390","article-title":"Antibodies gone bad - the molecular mechanism of light chain amyloidosis","volume":"290","author":"Absmeier","year":"2023","journal-title":"FEBS J"},{"issue":"6","key":"10.1016\/j.ejca.2026.117039_bib5","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL amyloidosis: mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement 2020 update","volume":"96","author":"Muchtar","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.ejca.2026.117039_bib6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.2024024623","article-title":"Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population","volume":"144","author":"Muchtar","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2026.117039_bib7","first-page":"67","article-title":"Systemic light chain amyloidosis, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.ejca.2026.117039_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.ejca.2026.117039_bib9","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMra2304088","article-title":"Systemic light chain amyloidosis","volume":"390","author":"Sanchorawala","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.117039_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"30","author":"Wechalekar","year":"2023","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.ejca.2026.117039_bib11","first-page":"853","article-title":"Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies","volume":"18","author":"Solomon","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"10.1016\/j.ejca.2026.117039_bib12","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1021\/bi0616605","article-title":"Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains","volume":"46","author":"O'Nuallain","year":"2007","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/j.ejca.2026.117039_bib13","article-title":"Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4","volume":"9","author":"Solomon","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.ejca.2026.117039_bib14","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.ejca.2026.117039_bib15","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.ejca.2026.117039_bib16","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2026.117039_bib17","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/leu.2016.191","article-title":"Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis","volume":"30","author":"Merlini","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.ejca.2026.117039_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009038","article-title":"Proposed cardiac end points for clinical trials in immunoglobulin light chain amyloidosis: report from the Amyloidosis Forum Cardiac Working Group","volume":"15","author":"Maurer","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"7","key":"10.1016\/j.ejca.2026.117039_bib19","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.ekir.2024.03.033","article-title":"Renal response criteria for clinical trials in amyloid light chain amyloidosis","volume":"9","author":"Leung","year":"2024","journal-title":"Kidney Int Rep"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:32:45Z","timestamp":1794000765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":19,"alternative-id":["S0959804926008208"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117039","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117039"}}